Clinical Trial

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

Study acronym: MEKinRAS
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2024 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
Trial Details
NCT Number NCT06555237
Lead Sponsor Medical University of Warsaw
Conditions Cardiomegaly, Noonan Syndrome
Enrollment 40 participants
Start Date 2024-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-15